Jessica L F Teh (Jessica L Teh, Jessica Teh)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Antiretroviral Therapy

Endoplasmic Reticulum

Estrogen Receptor

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

Cancer discovery

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Jessica L F Teh, Dan A Erkes, Phil Fang Cheng, Manoela Tiago, Nicole A Wilski, Conroy O Field, Inna Chervoneva, Mitch P Levesque, George X Xu, Reinhard Dummer, Andrew E Aplin
Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer immunology research 8 (9) (2020)
Jessica L F Teh, Timothy J Purwin, Anna Han, Vivian Chua, Prem Patel, Usman Baqai, Connie Liao, Nelisa Bechtel, Takami Sato, Michael A Davies, Julio Aguirre-Ghiso, Andrew E Aplin
Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Molecular cancer therapeutics 19 (8) (2020)
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, Fabio Savarese, Daniel Gerlach, Joseph R Marszalek, Michael P Sanderson, Dirk Kessler, Francesca Trapani, Heribert Arnhof, Klaus Rumpel, Dana-Adriana Botesteanu, Peter Ettmayer, Thomas Gerstberger, Christiane Kofink, Tobias Wunberg, Andreas Zoephel, Szu-Chin Fu, Jessica L F Teh, Jark Böttcher, Nikolai Pototschnig, Franziska Schachinger, Katharina Schipany, Simone Lieb, Christopher P Vellano, Jonathan C O'Connell, Rachel L Mendes, Jurgen Moll, Mark Petronczki, Timothy P Heffernan, Mark Pearson, Darryl B McConnell, Norbert Kraut
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer discovery 11 (1) (2020)